MAP3K5 and cardiac hypertrophy: Because cardiac fibrosis predisposes to heart failure, ASK1 inhibitors (in clinical trials for other fibrosis-associated diseases) may be therapeutically useful for hypertension-associated cardiac hypertrophy, reducing or preventing progression to heart failure in humans.